Calcium 500 mg and Vitamin D3 tablets manufactured by Life Max Cancer Laboratories were among the medicines that failed the quality test. The Central Drugs Standard Control Organization (CDSCO) has published its monthly report for September, which has identified 49 pharmaceutical products out of a total of 3,000 sampled medicines that do not meet the required quality standards.

CDSCO has also flagged four medicines manufactured by fake companies as spurious.

The non-standard medicines have been recalled on batch-wise basis as part of CDSCO’s efforts to ensure public safety.

According to CDSCO chief Rajeev Singh Raghuvanshi, only 1% of all drugs tested failed to meet quality standards, indicating that stringent monitoring measures are effectively controlling substandard drug production.

Some of the products marked include metronidazole tablets by Hindustan Antibiotics, domperidone tablets from Rainbow Life Sciences and oxytocin injection by Pushkar Pharma.

Other notable mentions were Metformin, Calcium 500 mg by Swiss Biotech Parenteral, Vitamin D3 250 IU Tablet by Life Max Cancer Laboratories, and Pan 40 from Alkem Labs. Paracetamol tablets produced by Karnataka Antibiotics and Pharmaceuticals Limited were particularly exposed for quality issues.

Additionally, the list also includes Gauze Roll Non-Sterile Roller Bandage and Diclofenac Sodium Tablet.

This monthly vigilance action by CDSCO is part of a concerted effort to reduce the presence of non-standard quality (NSQ) drugs in the market.